Eli Lilly and Company (LLY) Stock Rating Reaffirmed by BMO Capital Markets

Eli Lilly and Company (NYSE:LLY)‘s stock had its “underperform” rating restated by analysts at BMO Capital Markets in a report issued on Wednesday. They presently have a $71.00 target price on the stock, down from their previous target price of $73.00. BMO Capital Markets’ target price suggests a potential downside of 11.05% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $92.00 price target on shares of Eli Lilly and in a research report on Tuesday, May 16th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research report on Wednesday, July 26th. Finally, TheStreet cut Eli Lilly and from a “b+” rating to a “c” rating in a research note on Wednesday, May 31st. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $87.97.

Shares of Eli Lilly and (NYSE:LLY) traded up 0.58% during trading on Wednesday, reaching $80.28. The company’s stock had a trading volume of 726,152 shares. The stock has a market cap of $84.70 billion, a P/E ratio of 34.74 and a beta of 0.34. The stock has a 50-day moving average of $81.21 and a 200-day moving average of $82.05. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $86.72. Eli Lilly and also saw unusually large options trading on Monday. Stock investors purchased 7,401 put options on the company. This represents an increase of approximately 342% compared to the average volume of 1,675 put options.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the business posted $0.86 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. Analysts predict that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/09/06/eli-lilly-and-company-lly-stock-rating-reaffirmed-by-bmo-capital-markets.html.

In other news, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 849,733 shares of company stock valued at $70,436,087. Insiders own 0.20% of the company’s stock.

Several hedge funds have recently modified their holdings of LLY. BlackRock Inc. grew its position in shares of Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after acquiring an additional 59,978,664 shares during the period. Janus Henderson Group PLC grew its position in shares of Eli Lilly and by 7,093.5% during the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after acquiring an additional 9,223,251 shares during the period. Dodge & Cox grew its position in shares of Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after acquiring an additional 5,964,955 shares during the period. Renaissance Technologies LLC grew its position in shares of Eli Lilly and by 91.1% during the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after acquiring an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Eli Lilly and by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after acquiring an additional 2,181,701 shares during the period. 75.77% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)




Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

1 × three =